William M Souza,Mariene R Amorim,Renata Sesti-Costa,Lais D Coimbra,Natalia S Brunetti,Daniel A Toledo-Teixeira,Gabriela F de Souza,Stefanie P Muraro,Pierina L Parise,Priscilla P Barbosa,Karina Bispo-Dos-Santos,Luciana S Mofatto,Camila L Simeoni,Ingra M Claro,Adriana S S Duarte,Thais M Coletti,Audrey B Zangirolami,Carolina Costa-Lima,Arilson B S P Gomes,Lucas I Buscaratti,Flavia C Sales,Vitor A Costa,Lucas A M Franco,Darlan S Candido,Oliver G Pybus,Jaqueline G de Jesus,Camila A M Silva,Mariana S Ramundo,Giulia M Ferreira,Mariana C Pinho,Leandro M Souza,Esmenia C Rocha,Pamela S Andrade,Myuki A E Crispim,Grazielle C Maktura,Erika R Manuli,Magnun N N Santos,Cecilia C Camilo,Rodrigo N Angerami,Maria L Moretti,Fernando R Spilki,Clarice W Arns,Marcelo Addas-Carvalho,Bruno D Benites,Marco A R Vinolo,Marcelo A S Mori,Nelson Gaburo,Christopher Dye,Henrique Marques-Souza,Rafael E Marques,Alessandro S Farias,Michael S Diamond,Nuno R Faria,Ester C Sabino,Fabiana Granja,Jose Luiz Proença-Módena

Abstract:Background: Mutations accrued by SARS-CoV-2 lineage P.1-first detected in Brazil in early January, 2021-include amino acid changes in the receptor-binding domain of the viral spike protein that also are reported in other variants of concern, including B.1.1.7 and B.1.351. We aimed to investigate whether isolates of wild-type P.1 lineage SARS-CoV-2 can escape from neutralising antibodies generated by a polyclonal immune response. Methods: We did an immunological study to assess the neutralising effects of antibodies on lineage P.1 and lineage B isolates of SARS-CoV-2, using plasma samples from patients previously infected with or vaccinated against SARS-CoV-2. Two specimens (P.1/28 and P.1/30) containing SARS-CoV-2 lineage P.1 (as confirmed by viral genome sequencing) were obtained from nasopharyngeal and bronchoalveolar lavage samples collected from patients in Manaus, Brazil, and compared against an isolate of SARS-CoV-2 lineage B (SARS.CoV2/SP02.2020) recovered from a patient in Brazil in February, 2020. Isolates were incubated with plasma samples from 21 blood donors who had previously had COVID-19 and from a total of 53 recipients of the chemically inactivated SARS-CoV-2 vaccine CoronaVac: 18 individuals after receipt of a single dose and an additional 20 individuals (38 in total) after receipt of two doses (collected 17-38 days after the most recent dose); and 15 individuals who received two doses during the phase 3 trial of the vaccine (collected 134-230 days after the second dose). Antibody neutralisation of P.1/28, P.1/30, and B isolates by plasma samples were compared in terms of median virus neutralisation titre (VNT50, defined as the reciprocal value of the sample dilution that showed 50% protection against cytopathic effects). Findings: In terms of VNT50, plasma from individuals previously infected with SARS-CoV-2 had an 8·6 times lower neutralising capacity against the P.1 isolates (median VNT50 30 [IQR <20-45] for P.1/28 and 30 [<20-40] for P.1/30) than against the lineage B isolate (260 [160-400]), with a binominal model showing significant reductions in lineage P.1 isolates compared with the lineage B isolate (p≤0·0001). Efficient neutralisation of P.1 isolates was not seen with plasma samples collected from individuals vaccinated with a first dose of CoronaVac 20-23 days earlier (VNT50s below the limit of detection [<20] for most plasma samples), a second dose 17-38 days earlier (median VNT50 24 [IQR <20-25] for P.1/28 and 28 [<20-25] for P.1/30), or a second dose 134-260 days earlier (all VNT50s below limit of detection). Median VNT50s against the lineage B isolate were 20 (IQR 20-30) after a first dose of CoronaVac 20-23 days earlier, 75 (<20-263) after a second dose 17-38 days earlier, and 20 (<20-30) after a second dose 134-260 days earlier. In plasma collected 17-38 days after a second dose of CoronaVac, neutralising capacity against both P.1 isolates was significantly decreased (p=0·0051 for P.1/28 and p=0·0336 for P.1/30) compared with that against the lineage B isolate. All data were corroborated by results obtained through plaque reduction neutralisation tests. Interpretation: SARS-CoV-2 lineage P.1 might escape neutralisation by antibodies generated in response to polyclonal stimulation against previously circulating variants of SARS-CoV-2. Continuous genomic surveillance of SARS-CoV-2 combined with antibody neutralisation assays could help to guide national immunisation programmes. Funding: São Paulo Research Foundation, Brazilian Ministry of Science, Technology and Innovation and Funding Authority for Studies, Medical Research Council, National Council for Scientific and Technological Development, National Institutes of Health. Translation: For the Portuguese translation of the abstract see Supplementary Materials section.

Increased resistance of SARS-CoV-2 variant P.1 to antibody neutralization

Antibody evasion by the P.1 strain of SARS-CoV-2

Increased Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7 to Antibody Neutralization.

Ultrapotent Bispecific Antibodies Neutralize Emerging SARS-CoV-2 Variants

Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7

Bispecific Antibodies Targeting Distinct Regions of the Spike Protein Potently Neutralize SARS-CoV-2 Variants of Concern

Analysis of SARS-CoV-2 Variant Mutations Reveals Neutralization Escape Mechanisms and the Ability to Use ACE2 Receptors from Additional Species.

Structural basis for accommodation of emerging B.1.351 and B.1.1.7 variants by two potent SARS-CoV-2 neutralizing antibodies

Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera

Structural Basis for Potent Antibody Neutralization of SARS-CoV-2 Variants Including B.1.1.529

Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum

Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2

SARS-CoV-2 variants resist antibody neutralization and broaden host ACE2 usage

Neutralisation of SARS-CoV-2 lineage P.1 by antibodies elicited through natural SARS-CoV-2 infection or vaccination with an inactivated SARS-CoV-2 vaccine: an immunological study

Broadly potent anti-SARS-CoV-2 antibody shares 93% of epitope with ACE2 and provides full protection in monkeys

Spike mutations in SARS-CoV-2 variants confer resistance to antibody neutralization

Potent SARS-CoV-2 neutralizing antibodies with protective efficacy against newly emerged mutational variants

Antibodies elicited by SARS-CoV-2 infection and boosted by vaccination neutralize an emerging variant and SARS-CoV-1

Ten emerging SARS-CoV-2 spike variants exhibit variable infectivity, animal tropism, and antibody neutralization

Increased Resistance of SARS-CoV-2 Omicron Variant to Neutralization by Vaccine-Elicited and Therapeutic Antibodies